Skip to main
LUCD

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics is currently in a strong position for future growth with anticipated revenue increases and positive feedback from medical associations regarding their EsoGuard product, which has a potential $60 billion market. The company is also actively expanding their sales force and has a backlog of $40 million along with a potential $2 billion market opportunity for their EsoGuard test. While there are potential risks, analysts have a Buy rating on the stock and it is currently undervalued at a price of $2.50.

Bears say

Lucid Diagnostics is facing multiple challenges, including a decrease in EsoGuard tests processed in the first quarter of 2025, deferred revenue recognition, and a potentially smaller market opportunity compared to its estimated $2 billion. In addition, the company is still in its early stages of commercialization and has not yet gained Medicare coverage. There are also risks associated with obtaining regulatory approvals, gaining reimbursement from commercial payors, and competition in the medical diagnostics industry. These challenges pose significant risks to the company's financial performance and the attainment of its share price target.

Lucid Diagnostics (LUCD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Jun 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.